Atlas Trials

Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

Clinical trial NCT03371979 · COMPLETED

Trial details

NCT number
NCT03371979
Sponsor
Aeglea Biotherapeutics
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Small-cell Lung Cancer
Start date
2017-12-21
Primary completion
2021-01-01
Enrollment
68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.